SALT LAKE CITY, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic and genomic tumor testing and precision medicine, and INTERLINK Care Management, Inc.

Myriad Genetics, Inc. (MYGN), a genetic and genomic tumor testing and precision medicine provider, and INTERLINK Care Management, ...

SALT LAKE CITY - Myriad Genetics , Inc. (NASDAQ: NASDAQ:MYGN), a company specializing in genetic testing and precision medicine with annual revenues of $824 million, has announced the issuance of two ...

Emergen Research Logo The DNA Testing market is expected to grow from an estimated USD 12.51 billion in 2024 to USD 81.82 billion in 2033, ...

This research, published in Nature Genetics (2024), represents a major step toward understanding PTSD's genetic architecture. "The field of Psychiatry is in desperate need of early 'wins ...

London [UK]/ Munich [Germany]/ New Delhi [India], February 4: Datar Cancer Genetics (DCG) has launched Exacta AI, a next generation multi-analyte AI-driven platform providing optimized treatment ...

After hours: February 4 at 6:55:05 PM EST Loading Chart for MYGN ...

Navitas Semiconductor (Nasdaq: NVTS), the industry leader in next-generation GaNFast gallium nitride (GaN) and GeneSiC ...

Jan. 30, 2025 — A research group has developed new advanced light-controlled tools that enable precise control of proteins in real time in living cells. This groundbreaking research opens doors ...